Biogen (BIIB) PT Lowered to $340 at Goldman Sachs
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $225.36 --0%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 6 | New: 29
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 6 | New: 29
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter lowered the price target on Biogen (NASDAQ: BIIB) to $340.00 (from $393.00) while maintaining a Buy rating.
You May Also Be Interested In
- Rubrik Inc (RBRK) PT Raised to $139 at Baird
- Meridian Mining Plc (MNO:LN) PT Raised to GBP1.55 at Canaccord
- Elemental Royalty Corp (ELE) PT Lowered to $31 at H.C. Wainwright
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
